anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lactulose
Trial phase: Phase 2 | Phase 3
ATC code: A06AD11 | A06AD61
SMILES: OCC1OC(OC2C(CO)OC(O)(CO)C2O)C(O)C(O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Lactulose: Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.

In addition, outcome measurements will be completed at baseline and day 28.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of cirrhosis - must meet one of the following criteria:

liver biopsy, OR
history of cirrhosis complication: ascites, variceal bleeding, hepatic encephalopathy, OR

2 of the following 4 criteria:

Ultrasound, Computed tomography (CT) or Magnetic resonance imaging (MRI) findings of cirrhosis (cirrhotic appearing liver, splenomegaly, varices, ascites)
Fibroscan liver stiffness score >13 Kilopascal (kPa)
Laboratory testing: aspartate aminotransferase (AST)/platelet ratio index (APRI) >2.0

CT, MRI or Esophagogastroduodenoscopy (EGD) showing presence of esophageal varices

Exclusion Criteria:

Non-English speaking
Pregnancy (self-reported)
Unable or unwilling to provide consent
History of liver transplant
Disorientation at the time of enrollment, Dementia, or Treated Memory Disorder
History of prior lactulose use or HE within 6 months
Metastatic solid malignancy or blood malignancy
Hemoglobin A1C > 12 (within past year)
Intervention: Epiduo
Trial phase: Phase 4
SMILES: COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2.O=C(OOC(=O)c1ccccc1)c1ccccc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 11
Group description: interventions: Zinc gluconate (200g/capsule) one capsule once in the morning after breakfast for 60 days.

Adapalene 0.3% + benzoyl peroxide 2.5% gel to be applied once at night for 60 days.

Zinc gluconate: oral zinc gluconate 200mg

Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo]: Adapalene 0.3% + Benzoyl peroxide 2.5% gel applied once daily in the evening
Eligibility criteria:
Inclusion Criteria:

Filipino patients, aged 18-27 years old
New patients diagnosed with Acne Vulgaris with a Global Acne Grading System score of at least 19
Able to read and write in English or Tagalog
Seen at the Dermatology out-patient clinic of East Avenue Medical Center

Exclusion Criteria:

Patients with other chronic dermatoses or systemic disease
Taking oral supplements or medications within the past 4 weeks
Patients who are pregnant or lactating
Intervention: Methylprednisolone
Trial phase: Phase 4
ATC code: D07AA01 | D07CA02 | D10AA02 | H02AB04 | H02BX01 | S01CA08 | S03CA07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 4
Group description: 21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks

Methylprednisolone: 21 x 4mg tablets at 6 weeks, qualifying for MUA if ROM <90° at 8 weeks
Eligibility criteria:
Inclusion Criteria:

Any patient undergoing primary TKA with a diagnosis of osteoarthritis
≥ 18 years old
ROM <90° by 3 weeks postoperatively without improvement to >90° by 6 weeks
Requiring a 30-pill oxycodone refill
NSAID allergy
Thigh circumference discrepancy >2cm between legs from 3 to 6 weeks
Defense and Veterans Pain Rating Scale (DVPRS) > 5 between 3 and 6 weeks
Willingness to undergo randomization

Exclusion Criteria:

Reported chronic corticosteroid or opiate use
Suspected or confirmed periprosthetic joint infection
Revision TKA
Primary diagnosis other than osteoarthritis, including avascular necrosis, fracture, or post-traumatic arthritis
American Society of Anesthesiologists (ASA) score ≥ 4
Reported history of liver or renal disease
Uncontrolled diabetes
Immunosuppression
≤ 18 years old
Inability to take oral medications
Unable to provide consent
Intervention: Ceftriaxone
Trial phase: Phase 2
ATC code: J01DD04 | J01DD54
SMILES: CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CSC12)c1csc(N)n1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 5
Group description: The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.

Ceftriaxone: single intravenous dose of 1 g of ceftriaxone
Eligibility criteria:
Inclusion Criteria:

Written consent to participate in the study
Male or female greater than or equal to 18 years of age and less than 55 years of age
Is indicated for knee arthroscopy for cartilage or meniscal procedure
Ambulatory and in good general health
Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
Willing to abstain from use of protocol-restricted medications during the study

Exclusion Criteria:

Known allergic reactions to cephalosporins
Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
History of infection in either knee joint
Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
Other surgery or arthroscopy of either knee within 6 months of Screening
Intraarticular treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation or any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
Intraarticular treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
Females who are pregnant or nursing or plan to become pregnant during the study; men whose female partner plans to conceive during the study
Radiographic osteoarthritic changes defined as Kellgren-Lawrence grade 2 or greater (as determined by PI from patient's preoperative X-rays)
Inability to read and understand English
Any prior diagnosis of antibiotic-resistant diarrhea
Intervention: Furosemide
Trial phase: Phase 4
ATC code: C03CA01 | C03CB01 | C03EB01 | G01AE10
SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: ORKID Bundled Intervention: During the 90-day study period, participants will be prescribed outpatient hemodialysis with cooled dialysate (35-36°C), high sodium dialysate (145 mmol/L), a high ultrafiltration hold threshold (systolic blood pressure > 110 mmHg; ultrafiltration hold threshold will not be applied in participants with baseline systolic blood pressure < 120 mmHg), and high dose diuretics (160 mg oral furosemide twice daily) to be taken every day at home will also be prescribed. Dialysis will be weaned according to an active weaning protocol.

Furosemide: 160 mg oral furosemide twice daily to be taken every day at home
Eligibility criteria:
Inclusion Criteria:

AKI-D (acute kidney injury requiring dialysis), attributed at least in part to acute tubular necrosis by clinical nephrology team
Age ≥ 18 years
Pre-hospitalization eGFR ≥ 15 mL/min/1.73m2
Being discharged to a participating outpatient dialysis unit (within 30 miles of UCSF)

Exclusion Criteria:

Known loop diuretic allergy/intolerance
Dialysis duration > 3 months
Pregnant
Prisoner
Unable to consent
Clinical team declines to allow approach for study
Intervention: Amifostine
Trial phase: Phase 2
ATC code: V03AF05
SMILES: NCCCNCCSP(=O)(O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Amifostine: Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
Eligibility criteria:
Inclusion Criteria:

High risk Ewing's Sarcoma Family Tumors (ESFT) including Ewing's Sarcoma, Askin's tumor, peripheral PNET
High risk desmoplastic small round cell tumors (DSRCT)
Relapsed Wilm's tumor, diffuse anaplastic Wilm's tumor
High risk brain tumors including PNET/Medulloblastomas/germinomas
Relapsed germ cell tumors
Metastatic or relapsed rhabdoid tumors
Other relapsed/refractory pediatric embryonal tumors
Less than 30 years of age
Performance >= 50%
Cancer Diagnosis verification and staging
Disease Response and Recovery
Adequate Organ Function (Renal, Liver, Cardiac)

Exclusion Criteria:

Uncontrolled Infection
Pregnancy or Breastfeeding (For Females)
Disease Progression
Uncontrolled Intercurrent Illness
HIV Positive
Receiving other Investigational Agents
Amifostine Allergy
Intervention: Gabapentin
Trial phase: Phase 3
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients will receive 300mg gabapentin 3x a day after open thoracotomy

Gabapentin: Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
Eligibility criteria:
Inclusion criteria:

Pt undergoing open thoracotomy at Indiana University Hospital
ASA 1,2,3 or 4
Age 18 or older, male or female

Exclusion criteria:

History of substance abuse in the past 6 months which would include heroin, marijuana or any other illegal street drugs
Patient on home dose of gabapentin or pregabalin
Patient staying intubated after surgery
Patient above 70yo
Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day
Known allergy or other contraindications to the study medications, which include gabapentin
Patient unable to receive post-op epidural
BMI above 40
Creatinine clearance less than 30
Intervention: Gabapentin
Trial phase: Phase 3
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients will receive 300mg gabapentin once a day at night after open thoracotomy

Gabapentin: Gabapentin is a common medication used preoperatively and postoperatively as part of multimodal analgesia to help with acute pain.
Eligibility criteria:
Inclusion criteria:

Pt undergoing open thoracotomy at Indiana University Hospital
ASA 1,2,3 or 4
Age 18 or older, male or female

Exclusion criteria:

History of substance abuse in the past 6 months which would include heroin, marijuana or any other illegal street drugs
Patient on home dose of gabapentin or pregabalin
Patient staying intubated after surgery
Patient above 70yo
Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day
Known allergy or other contraindications to the study medications, which include gabapentin
Patient unable to receive post-op epidural
BMI above 40
Creatinine clearance less than 30
Intervention: Vimnerixin
Trial phase: Phase 2
SMILES: CC1CN(S(=O)(=O)Nc2cc(OC(C)C(O)CO)nc(SCc3ccc(F)cc3)n2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: RIST4721 400 mg: 4 active (100 mg) tablets once daily for 12 weeks

RIST4721: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Eligibility criteria:
Inclusion Criteria:

At least 6 months history of moderate or severe PPP, as defined by PPPASI ≥12 and PPPGA ≥3 at screening
Males and females must be willing to use birth control as indicated

Exclusion Criteria:

Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening
Breastfeeding or pregnant
Known immunodeficiency or subject is immunocompromised
Active/latent infection with HBV, HCV, HIV, SARS-CoV-2 or TB
Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization
Intervention: Gallium Ga-68 gozetotide
Trial phase: Phase 3
ATC code: V09IX14
SMILES: O=C([O-])CCc1ccc(O)c(CN(CCN(CC(=O)[O-])Cc2cc(CCC(=O)NCCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)ccc2O)CC(=O)[O-])c1.[68Ga+3]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: The intervention is a PET scan with the radiolabelled PSMA ligand, 68Ga-PSMA-11. The PET may be combined with a CT scan as a PET/CT or an MRI scan as PET/MRI. 68Ga-PSMA-11 PET/CT will be acquired using a modern digital GE PET/CT scanner or a modern digital PET / MRI scanner.

Ga-PSMA-11: The PSMA Sterile Cold Kit, is a kit comprising all needed materials (lyophilized PSMA for PSMA reconstitution, elution vial for Ga and ancillary materials for transfer between vials) to perform a room-temperature radiolabelling of PSMA-11 with Ga. Ga is not part of the kit and should be provided in the form gallium chloride solution following the requirements of the relevant local regulations. PSMA-11 radiolabelled with Ga is administered in patients with prostate cancer recurrence after radical treatment.
Eligibility criteria:
Inclusion Criteria:

Histopathologically proven prostate adenocarcinoma
Age ≥ 18 years
Patients already diagnosed with prostate cancer: Primary Staging: intermediate and high-risk patients per NCCN guidelines

Biochemical Recurrence: Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy):

a. Post radical prostatectomy (RP) - AUA recommendation i. PSA greater than or equal to 0.2 ng/mL measured more than 6-13 weeks after RP and confirmed by a second determination of a PSA level of >0.2 ng/mL b. Post-radiation therapy - ASTRO-Phoenix consensus definition i. Nadir + greater than or equal to 2 ng/mL rise in PSA

Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

Unable to lie flat, still or tolerate a PET/CT scan, or any other condition that would preclude PET/CT imaging.
Patients with any medical condition or circumstance that the investigator believes may compromise the data collection or lead to a failure to fulfil the study requirements.
Patients with known hypersensitivity to the active substance or to any of the excipients of the investigational product.
Intervention: Cannabidiol
Trial phase: Phase 4
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Participants will self-administer CBD daily for 2 months.

CBD oil: -Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc ~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).

-The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration
Eligibility criteria:
Inclusion Criteria:

Willingness to take CBD and to participate in follow up for two months
Older than 21 and younger than 60
Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count <350cells/ml)

Exclusion Criteria:

Conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis
All medications that may affect inflammation such as aspirin, steroids, statins; CD4 count <350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)
UF(University of Florida)/Shands staff and students will not be considered for enrollment
Intervention: SILVER DIAMMINE FLUORIDE
Trial phase: Phase 3
SMILES: N.N.[Ag+].[F-]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 50
Group description: These active caries lesions will receive silver diamine fluoride treatment
Eligibility criteria:
Inclusion Criteria:

The presence of at least one active carious lesion on a primary tooth.
Completion of an informed consent to participate in the study.

Exclusion criteria:

Children reporting spontaneous or elicited pain from caries or showing any signs of pulpal infection, swelling, abscess, obvious discoloration of the tooth, or premature mobility.
Reported usage of local or systemic antibiotics, chlorhexidine or fluoride mouthwashes within the last 2 weeks.
Children presenting with special health care needs or undergoing medical treatment for chronic or acute diseases affecting salivary flow.
Allergy or sensitivity to silver or any of the materials included in the study.
Child weight less than 10 Kg (to avoid concerns for toxicity).
Intervention: Clopidogrel
Trial phase: Phase 4
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 69
Group description: Subjects with high bleeding risk (HBR) on dual antiplatelet therapy (DAPT) with clopidogrel and aspirin, that underwent successful percutaneous coronary intervention (PCI) were stratified by the CYP2C19 loss-of-function (LOF) allele within one week of DAPT initiation. In this group, subjects identified as CYp2C19*2 or*3 LOF allele non-carriers continued with clopidogrel monotherapy.

Clopidogrel: 75 mg/day
Eligibility criteria:
Inclusion Criteria:

Informed consent in adults
Successful percutaneous coronary intervention (PCI) [no non-fatal myocardial infarction (MI)/stroke/repeat target revascularization/bleeding/acute kidney injury].
Academic research consortium-high bleeding risk (ARC-HBR) score ≥ 4.

Exclusion Criteria:

Chronic use of warfarin or direct oral anticoagulant (DOAC).
Unsuccessful PCI (see above).
Lesions with angiographic thrombus.
Prior PCI within 6 months.
Planned PCI or surgical intervention to treat any cardiac or noncardiac condition within 6 months.
High risk lesion/stent characteristics (> 50% unprotected left main disease, bifurcation disease requiring 2 stents technique, rotational atherectomy.
Vein graft.
Unprotected left main intervention or history of definite stent thrombosis.
Women of child-bearing age unless negative pregnancy test is done.
Life expectancy < 1 year.
Known drug/alcohol dependence.
Assessment that the patient will not be compliant with the study protocol.
Intervention: (2-{7-[2-(4-Cyano-2-fluoro-phenoxy)-ethyl]-9-oxa-3,7-diaza-bicyclo[3.3.1]non-3-yl}-ethyl)-carbamic acid tert-butyl ester
Trial phase: Phase 3
SMILES: CC(C)(C)OC(=O)NCCN1CC2CN(CCOc3ccc(C#N)cc3F)CC(C1)O2
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: One drop of study medication in each eye.

Phentolamine Ophthalmic Solution 0.75%: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Eligibility criteria:
Inclusion Criteria:

Males or premenstrual females 3 to 11 years of age
Ability to comply with all protocol-mandated procedures independently and to attend all scheduled office visits
Parent/Legal guardian willing to give written informed consent to participate in this study. Children aged 7 to 11 years to provide signed assent form, as well as a separate parental/legal guardian consent.

Exclusion Criteria:

Clinically significant ocular disease as deemed by the Investigator(eg, amblyopia, congenital cataract, congenital glaucoma) that might interfere with the study
Unwilling or unable to discontinue use of contact lenses at screening until study completion
Unwilling or unable to suspend use of topical medication at screening until study completion
Ocular trauma or ocular surgery within the 6 months prior to screening
Use of any topical prescription or over-the-counter (OTC)ophthalmic medications of any kind within 7 days of screening
Recent or current evidence of ocular infection or inflammation in either eye (such as current evidence of clinically significant blepharitis, conjunctivitis, or keratitis). Subjects must be symptom-free for at least 7 days prior to screening
Closed or very narrow-angle that in the Investigator's opinion is potentially occludable if the subject's pupil is dilated
History of any traumatic (surgical or nonsurgical) or non-traumatic condition affecting the pupil or iris

Known allergy, hypersensitivity, or contraindication to any component of the phentolamine ophthalmic solution or to any component of the mydriatic agents or vehicle formulation

Systemic:

Known hypersensitivity or contraindication to α- and/or β-adrenoceptor antagonists
Clinically significant systemic disease (eg, uncontrolled diabetes, cancer, hepatic, renal, endocrine, or cardiovascular disorders) that in the opinion of the Investigator could interfere with the study
Subjects with learning disabilities that in the opinion of the investigator could interfere with the study
Initiation of treatment with or any changes to the current dosage, drug, or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to screening or during the study(Appendix 4)
Participation in any investigational study within 30 days prior to screening
Intervention: Ketamine
Trial phase: Phase 3
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Following surgery and extubation, patients will receive ketamine 0.5 mg/kg over 10 minutes followed by an infusion of 0.3 mg/kg/h for 2 hours 50 minutes.

Ketamine: NMDA antagonist
Eligibility criteria:
Inclusion Criteria:

Able to provide written, informed consent
Aged 18 or older
Scheduled for non-ambulatory surgery scheduled to last at least 2 hours at Barnes-Jewish Hospital

Past medical history of depression, defined as one or more of the following criteria

Previous diagnosis by a psychiatrist or primary care physician in an outpatient or inpatient setting, by patient report or chart documentation
Prescription of an oral antidepressant by a psychiatrist or primary care physician for a mood disorder

Exclusion Criteria:

Bipolar depression
Concurrent use of a medication contraindicated with ketamine
Emergent surgery
Known or suspected elevation in intracranial pressure
Current subarachnoid hemorrhage
Carotid endarterectomy or arteriovenous malformation repair
Allergy to ketamine
Any condition in which a significant elevation of blood pressure would constitute a serious hazard (e.g., aortic dissection, pheochromocytoma)
Known history of dementia
Pregnancy or lactation
Inability to converse in English
Concurrent enrollment in another interventional trial